Atlas Trials

Acute Myeloid Leukemia With KMT2A Rearrangement

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Acute Myeloid Leukemia With KMT2A Rearrangement

RecordFirmDate
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease (NCT05886049)National Cancer Institute (NCI)2024-06-20
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation (NCT06222580)Uma Borate2024-02-20

Track Acute Myeloid Leukemia With KMT2A Rearrangement automatically

Every clearance here is in the API, with alerts when new ones post.